Radiopharm Theranostics Ltd

424B5 priced

Gross proceeds $18,900,000

Radiopharm Theranostics Ltd. has filed a prospectus supplement (424B5) to offer up to $18.9 million in American Depositary Shares (ADSs) through Leerink Partners LLC as sales agent. The ADSs, representing 300 ordinary shares each, are listed on Nasdaq under RADX. The offering is part of an at-the-market sales agreement, with Leerink Partners receiving a 3.0% commission. The filing references the company's ongoing development of radiopharmaceutical therapies and compliance with regulatory requirements.

424B3 priced

140,999,999 shares

Radiopharm Theranostics Ltd's current 424B3 filing relates to the registration of 140,999,999 ordinary shares and 140,999,999 ordinary shares underlying options, following a Private Placement in October 2025 where 1.166 billion shares were sold to institutional investors for A$35 million. The filing enables Selling Shareholders to convert ordinary shares into American Depositary Shares (ADSs) representing 300 ordinary shares each, with ADSs listed on Nasdaq under RADX. The company will not receive proceeds from ADS sales but will benefit from option exercises. The filing emphasizes risks associated with market volatility, regulatory uncertainties, and the company's status as an emerging growth and foreign private issuer.

EFFECT effective

Radiopharm Theranostics Ltd's Form F-3 registration statement became effective on December 23, 2025, enabling Selling Shareholders to offer 140,999,999 ordinary shares and 470,000 American Depositary Shares (ADSs) representing 300 ordinary shares each. The filing relates to shares purchased in a October 2025 private placement and associated options. The company will not receive proceeds from ADS sales but will benefit from option exercises. ADSs are listed on Nasdaq under RADX, while ordinary shares trade on the ASX under RAD.

EFFECT effective

Radiopharm Theranostics Ltd's Form F-3 registration statement became effective on December 23, 2025, with a new file number (333-292198) compared to the previous filing (333-292178). The notice of effectiveness confirms the SEC's approval for the securities offering.

20-F supplemental

Radiopharm Theranostics Ltd, an Australian biotechnology company incorporated in 2021, operates in the theranostics sector with drug candidates targeting oncology. The company faces significant risks, including historical operating losses, dependence on external funding, and challenges in clinical trials and regulatory approvals. Its financial statements are prepared under IFRS, and it is listed on the ASX and Nasdaq. The filing highlights ongoing risks related to commercialization, intellectual property, and market competition.

424B3 priced

157,420,500 shares

The current 424B3 filing serves as a prospectus for the resale of up to 157,420,500 ordinary shares (represented by 524,735 American Depositary Shares) and 78,710,642 ordinary shares underlying options by selling shareholders. The shares were initially issued in a June 2024 private placement, with proceeds from ADS sales going to the selling shareholders. The filing outlines the plan for resale, including open market transactions, negotiated sales, and pricing mechanisms tied to market conditions. The ADSs are listed on Nasdaq under RADX, and the document emphasizes risks associated with the investment, referencing a dedicated Risk Factors section.

EFFECT effective

Radiopharm Theranostics Ltd filed a Form F-1 registration statement, confirming the effectiveness of its securities offering. The filing relates to the resale of up to 157,420,500 ordinary shares via 524,735 American Depositary Shares (ADSs) and 78,710,642 underlying options from a June 2024 private placement. The ADSs are listed on Nasdaq under RADX, with proceeds from sales going to selling shareholders. The company is an emerging growth company and foreign private issuer, impacting reporting requirements.

F-1 filed

157,420,500 shares

Radiopharm Theranostics Ltd, an Australian biotechnology company, is registering 157,420,500 ordinary shares and 78,710,642 shares underlying options through a prospectus. The offering involves American Depositary Shares (ADS) representing 300 ordinary shares each, listed on Nasdaq. The company focuses on developing radiopharmaceutical therapies for precision oncology, with plans for regulatory approvals in multiple jurisdictions. Proceeds from the offering will be used for commercialization and operational needs.

CERT inactive

The current filing is a CERT form for Radiopharm Theranostics Ltd, but the text content is encrypted/invalid and contains no readable information. The previous filing was a Notice of Effectiveness for Form F-6 dated September 18, 2024.

EFFECT effective

Radiopharm Theranostics Ltd, an Australian biotech company, received SEC effectiveness for its Form F-6 registration statement, enabling a secondary listing on Nasdaq via American Depositary Shares (ADS). The filing confirms the company's transition from a confidential submission (DRS) to an effective registration, with details on its capital structure, financial reporting under IFRS, and forward-looking statements about product development, regulatory approvals, and market expansion.

DRS filed

Radiopharm Theranostics Ltd, an Australian company incorporated in 2021, is preparing for a secondary listing on Nasdaq via American Depositary Shares (ADS). The filing outlines its focus on developing radiopharmaceutical products for diagnostic and therapeutic uses, with no product revenue generated to date. The company operates as a clinical-stage entity, emphasizing research and development (R&D) while disclosing significant historical operating losses and reliance on external financing for future growth.